Analysis of Reportable Segments
Becton, Dickinson & Co. operates in 3 segments: BD Medical; BD Life Sciences; and BD Interventional.
Segment Profit Margin
Becton, Dickinson & Co., profit margin by reportable segment
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | |
|---|---|---|---|---|---|---|
| BD Medical | 27.25% | 26.20% | 31.16% | 30.45% | 25.70% | 22.69% |
| BD Life Sciences | 36.62% | 30.05% | 29.02% | 27.88% | 19.36% | 20.71% |
| BD Interventional | 22.01% | 19.25% | 23.00% | 10.08% | 36.20% | 35.56% |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | BD Medical | BD Medical segment profit margin ratio deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
| BD Life Sciences | BD Life Sciences segment profit margin ratio improved from 2019 to 2020 and from 2020 to 2021. | |
| BD Interventional | BD Interventional segment profit margin ratio deteriorated from 2019 to 2020 but then improved from 2020 to 2021 not reaching 2019 level. |
Segment Profit Margin: BD Medical
Becton, Dickinson & Co.; BD Medical; segment profit margin calculation
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | |
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Segment operating income | 2,583) | 2,274) | 2,824) | 2,624) | 1,907) | 1,807) |
| Revenues | 9,479) | 8,680) | 9,064) | 8,616) | 7,419) | 7,965) |
| Segment Profitability Ratio | ||||||
| Segment profit margin1 | 27.25% | 26.20% | 31.16% | 30.45% | 25.70% | 22.69% |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
1 2021 Calculation
Segment profit margin = 100 × Segment operating income ÷ Revenues
= 100 × 2,583 ÷ 9,479 = 27.25%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | BD Medical | BD Medical segment profit margin ratio deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
Segment Profit Margin: BD Life Sciences
Becton, Dickinson & Co.; BD Life Sciences; segment profit margin calculation
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | |
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Segment operating income | 2,391) | 1,405) | 1,248) | 1,207) | 772) | 793) |
| Revenues | 6,530) | 4,675) | 4,300) | 4,330) | 3,988) | 3,829) |
| Segment Profitability Ratio | ||||||
| Segment profit margin1 | 36.62% | 30.05% | 29.02% | 27.88% | 19.36% | 20.71% |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
1 2021 Calculation
Segment profit margin = 100 × Segment operating income ÷ Revenues
= 100 × 2,391 ÷ 6,530 = 36.62%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | BD Life Sciences | BD Life Sciences segment profit margin ratio improved from 2019 to 2020 and from 2020 to 2021. |
Segment Profit Margin: BD Interventional
Becton, Dickinson & Co.; BD Interventional; segment profit margin calculation
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | |
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Segment operating income | 933) | 724) | 903) | 306) | 248) | 245) |
| Revenues | 4,239) | 3,762) | 3,926) | 3,037) | 685) | 689) |
| Segment Profitability Ratio | ||||||
| Segment profit margin1 | 22.01% | 19.25% | 23.00% | 10.08% | 36.20% | 35.56% |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
1 2021 Calculation
Segment profit margin = 100 × Segment operating income ÷ Revenues
= 100 × 933 ÷ 4,239 = 22.01%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | BD Interventional | BD Interventional segment profit margin ratio deteriorated from 2019 to 2020 but then improved from 2020 to 2021 not reaching 2019 level. |
Segment Capital Expenditures to Depreciation
Becton, Dickinson & Co., capital expenditures to depreciation by reportable segment
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | |
|---|---|---|---|---|---|---|
| BD Medical | 0.68 | 0.43 | 0.54 | 0.54 | 0.63 | 0.58 |
| BD Life Sciences | 0.84 | 0.67 | 0.81 | 0.93 | 0.83 | 0.79 |
| BD Interventional | 0.16 | 0.16 | 0.14 | 0.10 | 0.31 | 0.32 |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
| Segment financial ratio | Reportable segment | The company |
|---|---|---|
| Segment capital expenditures to depreciation | BD Medical | BD Medical segment capital expenditures to depreciation ratio deteriorated from 2019 to 2020 but then improved from 2020 to 2021 exceeding 2019 level. |
| BD Life Sciences | BD Life Sciences segment capital expenditures to depreciation ratio deteriorated from 2019 to 2020 but then improved from 2020 to 2021 exceeding 2019 level. | |
| BD Interventional | BD Interventional segment capital expenditures to depreciation ratio improved from 2019 to 2020 and from 2020 to 2021. |
Segment Capital Expenditures to Depreciation: BD Medical
Becton, Dickinson & Co.; BD Medical; segment capital expenditures to depreciation calculation
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | |
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Capital expenditures | 777) | 477) | 577) | 560) | 486) | 464) |
| Depreciation and amortization | 1,140) | 1,104) | 1,073) | 1,028) | 773) | 801) |
| Segment Financial Ratio | ||||||
| Segment capital expenditures to depreciation1 | 0.68 | 0.43 | 0.54 | 0.54 | 0.63 | 0.58 |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
1 2021 Calculation
Segment capital expenditures to depreciation = Capital expenditures ÷ Depreciation and amortization
= 777 ÷ 1,140 = 0.68
| Segment financial ratio | Reportable segment | The company |
|---|---|---|
| Segment capital expenditures to depreciation | BD Medical | BD Medical segment capital expenditures to depreciation ratio deteriorated from 2019 to 2020 but then improved from 2020 to 2021 exceeding 2019 level. |
Segment Capital Expenditures to Depreciation: BD Life Sciences
Becton, Dickinson & Co.; BD Life Sciences; segment capital expenditures to depreciation calculation
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | |
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Capital expenditures | 297) | 192) | 230) | 255) | 212) | 200) |
| Depreciation and amortization | 352) | 286) | 284) | 275) | 254) | 254) |
| Segment Financial Ratio | ||||||
| Segment capital expenditures to depreciation1 | 0.84 | 0.67 | 0.81 | 0.93 | 0.83 | 0.79 |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
1 2021 Calculation
Segment capital expenditures to depreciation = Capital expenditures ÷ Depreciation and amortization
= 297 ÷ 352 = 0.84
| Segment financial ratio | Reportable segment | The company |
|---|---|---|
| Segment capital expenditures to depreciation | BD Life Sciences | BD Life Sciences segment capital expenditures to depreciation ratio deteriorated from 2019 to 2020 but then improved from 2020 to 2021 exceeding 2019 level. |
Segment Capital Expenditures to Depreciation: BD Interventional
Becton, Dickinson & Co.; BD Interventional; segment capital expenditures to depreciation calculation
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | |
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Capital expenditures | 125) | 119) | 120) | 65) | 16) | 18) |
| Depreciation and amortization | 769) | 750) | 881) | 658) | 52) | 56) |
| Segment Financial Ratio | ||||||
| Segment capital expenditures to depreciation1 | 0.16 | 0.16 | 0.14 | 0.10 | 0.31 | 0.32 |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
1 2021 Calculation
Segment capital expenditures to depreciation = Capital expenditures ÷ Depreciation and amortization
= 125 ÷ 769 = 0.16
| Segment financial ratio | Reportable segment | The company |
|---|---|---|
| Segment capital expenditures to depreciation | BD Interventional | BD Interventional segment capital expenditures to depreciation ratio improved from 2019 to 2020 and from 2020 to 2021. |
Revenues
Becton, Dickinson & Co., revenues by reportable segment
US$ in millions
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | |
|---|---|---|---|---|---|---|
| BD Medical | 9,479) | 8,680) | 9,064) | 8,616) | 7,419) | 7,965) |
| BD Life Sciences | 6,530) | 4,675) | 4,300) | 4,330) | 3,988) | 3,829) |
| BD Interventional | 4,239) | 3,762) | 3,926) | 3,037) | 685) | 689) |
| Total | 20,248) | 17,117) | 17,290) | 15,983) | 12,092) | 12,483) |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
Segment operating income
Becton, Dickinson & Co., segment operating income by reportable segment
US$ in millions
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | |
|---|---|---|---|---|---|---|
| BD Medical | 2,583) | 2,274) | 2,824) | 2,624) | 1,907) | 1,807) |
| BD Life Sciences | 2,391) | 1,405) | 1,248) | 1,207) | 772) | 793) |
| BD Interventional | 933) | 724) | 903) | 306) | 248) | 245) |
| Total | 5,907) | 4,403) | 4,975) | 4,137) | 2,927) | 2,845) |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
Capital expenditures
Becton, Dickinson & Co., capital expenditures by reportable segment
US$ in millions
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | |
|---|---|---|---|---|---|---|
| BD Medical | 777) | 477) | 577) | 560) | 486) | 464) |
| BD Life Sciences | 297) | 192) | 230) | 255) | 212) | 200) |
| BD Interventional | 125) | 119) | 120) | 65) | 16) | 18) |
| Corporate and All Other | 32) | 22) | 30) | 15) | 13) | 11) |
| Total | 1,231) | 810) | 957) | 895) | 727) | 693) |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
Depreciation and amortization
Becton, Dickinson & Co., depreciation and amortization by reportable segment
US$ in millions
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | |
|---|---|---|---|---|---|---|
| BD Medical | 1,140) | 1,104) | 1,073) | 1,028) | 773) | 801) |
| BD Life Sciences | 352) | 286) | 284) | 275) | 254) | 254) |
| BD Interventional | 769) | 750) | 881) | 658) | 52) | 56) |
| Corporate and All Other | 12) | 14) | 15) | 17) | 9) | 3) |
| Total | 2,273) | 2,154) | 2,253) | 1,978) | 1,088) | 1,114) |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).